PD01-05: Real World Experience of Enfortumab vedotin in Advanced Urothelial Carcinoma: Preliminary results in a Single Center
Enfortumab vedotin應用於晚期尿路上皮癌:單一醫學中心經驗
張家郡1、吳錫金1,2,3、楊啟瑞1、黃志平1,2、林精湛4、林哲弘4、張議徽1、蔡禮賢1、張兆祥1,2
1中國醫藥大學附設醫院 泌尿部；中國醫藥大學 醫學系2；3中國醫藥大學北港附設醫院泌尿科；4中國醫藥大學附設醫院 內科部 血液腫瘤科
Real World Experience of Enfortumab vedotin in Advanced Urothelial Carcinoma: Preliminary results in a Single Center
Jia-Jyun Jhang1, Hsi-Chin Wu1,2,3, Chi-Rei Yang1, Chi-Ping Huang1,2, Ching-Chan Lin4, Che-Hung Lin4, Yi-Huei Chang1, Li-Hsien Tsai1, Chao-Hsiang Chang1,2
1Department of Urology, China Medical University Hospital, Taichung, Taiwan; 2 School of Medicine, China Medical University, Taichung, Taiwan; 3Department of Urology, China Medical University Beigang Hospital, Yunlin, Taiwan; 4Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan
Purpose: Enfortumab vedotin, an antibody-drug conjugate (ADC) targeting nectin-4, a transmembrane protein highly expressed in urothelial carcinoma, has shown promising treatment efficacy in recent trials, encompassing both previously treated and untreated cases of locally advanced or metastatic urothelial carcinoma. We aim to study the treatment outcome and adverse events of Enfortumab vedotin in the real-world setting.
Materials and Methods: We retrospectively studied patients with locally advanced or metastasis urothelial carcinoma who received treatment with Enfortumab vedotin between October 2021 and March 2024 at China Medical University Hospital. Baseline characteristics such as age, gender, weight, primary disease origin sites, prior therapies, metastasis sites, previous surgeries, staging, and Bellmunt risk score were recorded. Patient’s treatment including treatment dosage and regimen, treatment response, and adverse events were documented.
Results: 25 patients were included in our study, including 15 males (60%) and 10 females (40%). 16 patients (64%) originated from the upper urinary tract, while 9 patients (36%) had bladder origin. At baseline, 14 patients (56%) received chemotherapy, 11 patients (44%) received immunotherapy, and 9 patients (36%) did not undergo previous systemic therapy. The objective response rate (ORR) was 56%, with 3 patients (12%) achieving complete response (CR) and 11 patients (44%) achieving partial response (PR). 5 patients (20%) demonstrated stable disease (SD) as their best response, while 6 patients (24%) experienced disease progression (PD). Treatment-related adverse events (AEs) were observed in 23 patients (92%), with 2 patients (8%) requiring dose reductions due to AEs and 5 patients (20%) experiencing treatment interruptions. There was no patient who withdraw from the treatment due to AE, nor was there treatment related AE that result in death.
Conclusions: The preliminary results of our study indicate that Enfortumab vedotin demonstrates a satisfactory treatment response with manageable adverse events in both previously treated and untreated advanced urothelial carcinoma cases within a real-world context, consistent with prior published trial outcomes. Notably, the higher proportion of upper tract urothelial carcinoma patients observed in our study compared to those in the trials reflects the distinctive epidemiology of urothelial carcinoma in Taiwan. Further investigation is warranted to gain a deeper understanding of the long-term treatment efficacy of Enfortumab vedotin within our population.